ArticleDiagnostics (Basel, Switzerland)2018
A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.
Article in Diagnostics (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Detection ofBiomolecules · 2021Trial
- Circulating biomarkers in HPV-associated oropharyngeal cancer: Clinical applications of liquid biopsy in diagnosis, prognosis, and surveillance.The journal of liquid biopsy · 2025Review
- Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.Journal of biomedical science · 2023Review
- Identification of Somatic Mutations in Plasma Cell-Free DNA from Patients with Metastatic Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2023Article
- Allele-Specific PCR for PIK3CA Mutation Detection Using Phosphoryl Guanidine Modified Primers.Diagnostics (Basel, Switzerland) · 2023Article
- Development of a multiplex allele-specific qPCR approach for testing PIK3CA mutations in patients with colorectal cancer.Heliyon · 2022Article
- Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.Heliyon · 2022Article
- Review
- Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine.Diagnostics (Basel, Switzerland) · 2022Review
- Liquid Biopsy in Squamous Cell Carcinoma of the Esophagus and of the Head and Neck.Frontiers in medicine · 2022Review
- Gene Mutations in Circulating Tumour DNA as a Diagnostic and Prognostic Marker in Head and Neck Cancer-A Systematic Review.Biomedicines · 2021Review
- Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond.British journal of cancer · 2021Review
- The Prognostic Significance of Immune-Related Metabolic Enzyme MTHFD2 in Head and Neck Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2020Article
- Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort.Cancer management and research · 2020Article
- PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPIK3CA pathways are the most frequently mutated oncogenic pathway in head and neck squamous cell carcinoma (HNSCC), including virally driven HNCs. PIK3CA is involved in the PI3K-PTEN-mTOR signalling pathway. PIK3CA has been implicated in HNSCC progression and PIK3CA mutations may serve as predictive biomarkers for therapy selection. Circulating tumour DNA (ctDNA) derived from necrotic and apoptotic tumour cells are thought to harbour tumour-specific genetic alterations. As such, the detection of PIK3CA alterations detected by ctDNA holds promise as a potential biomarker in HNSCC.
methodsBlood samples from treatment naïve HNSCC patients (
resultsIn this pilot, cross sectional study, PIK3CA E545K mutation was detected in the plasma samples of 9/29 HNSCC patients using the Plex-PCR
conclusionThe results of this pilot study support the notion of using allele-specific technologies for cost-effective testing of ctDNA, and further assert the potential utility of ctDNA in HNSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.